Product Pipeline
03/05/2003 Corixa to present at Invest Northwest, Roth Capital Partners and SG Cowen conferences in March
02/24/2003 Corixa reports fourth quarter and year-end results
Results meet 2002 earnings guidance
02/24/2003 The European Commission designates tositumomab and Iodine 131 radiolabelled tositumomab (BEXXAR therapy) as an orphan medicinal product
02/13/2003 Conference Call/Webcast Alert
Corixa Corporation 4th quarter and year-end 2002 earnings conference call
02/12/2003 Corixa to present at Nomura and BIO CEO conferences in February
02/04/2003 Corixa provides update on lung cancer vaccine program
Reacquires North American rights to lung cancer vaccines from Japan Tobacco Inc.
01/29/2003 Corixa and GSK Bio to collaborate on cancer vaccine development; Corixa to acquire ovarian cancer product development rights
Discovery phase of research agreement covering cancer vaccines now complete; infectious disease antigen discovery and development ongoing
01/13/2003 Corixa and IDRI initiate U.S. Phase I trial of leishmaniasis vaccine
01/08/2003 Corixa licenses antigen to Purdue Pharma
Purdue exercises option to license Corixa antigen following successful collaboration
A business overview as well as information on Corixa's partners, management team, employment opportunities, and company contacts.
Corixa's near-term products and adjuvant for research applications.
Product pipeline, therapeutic areas of focus, products, technology platforms, and publications.
Company reports, stockholder letter, events calendar, stock quote, analyst list, and materials request.
Current and archived company press releases.
Current and archived company press releases.